製品の概要

製品の詳細

  • 由来Recombinant
  • 由来Escherichia coli
  • アミノ酸配列
    • 生物種Human
    • 配列SGLGRSRRGG RSRVDQEERF PQGLWTGVAM RSCPEEQYWD PLLGTCMSCK TICNHQSQRT CAAFCRSLSC RKEQGKFYDH LLRDCISCAS ICGQHPKQCA YFCENKLRSP VNLPPELRRQ RSGEVENNSD NSGRYQGLEH RGSEASPALP GLKLSADQV
    • 領域1 to 159

関連製品

特性

Our Abpromise guarantee covers the use of ab50090 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • アプリケーション

    SDS-PAGE

    Functional Studies

  • エンドトキシン・レベル< 0.100 Eu/µg
  • 精製度> 95 % SDS-PAGE.
    ab50090 purity was assessed also by HPLC. Endotoxin level is less than 0.1 ng per µg (1EU/µg).
  • 製品の状態Lyophilised
  • 備考


    Soluble TACI inhibits APRIL-stimulated proliferation of primary B-cells by blocking the binding of APRIL to the membrane anchored TACI receptor.

  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. The lyophilized protein is stable for a few weeks at room temperature. Store at -20°C long term.

  • 再構成Reconsitute to 1mg/ml in distilled water.

関連情報

  • 別名
    • CD 267
    • CD267
    • CD267 antigen
    • CVID
    • CVID2
    • FLJ39942
    • MGC133214
    • MGC39952
    • OTTHUMP00000065442
    • TNFRSF 13B
    • TNFRSF 14B
    • TNFRSF13B
    • TNFRSF13B protein
    • TNFRSF14B
    • TR13B_HUMAN
    • Transmembrane activator and CAML interactor
    • Tumor necrosis factor receptor 13B
    • Tumor necrosis factor receptor superfamily member 13B
    see all
  • 機能Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
  • 組織特異性Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
  • 関連疾患Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2) [MIM:240500]. CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology.
  • 配列類似性Contains 2 TNFR-Cys repeats.
  • 細胞内局在Membrane.
  • Information by UniProt

Recombinant Human TACI protein (ab50090) 使用論文

ab50090 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab50090.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"